Company

Chugai Pharmaceutical Co. Ltd

Headquarters: Tokyo, Japan

Employees: 7,664

CEO: Dr. Osamu Okuda

JPX: 4519 +0.14%

Market Cap

¥8.865 Trillion

JPY as of Jan. 1, 2024

US$62.94 Billion

Market Cap History

Chugai Pharmaceutical Co. Ltd market capitalization over time

Evolution of Chugai Pharmaceutical Co. Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Chugai Pharmaceutical Co. Ltd

Detailed Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Chugai Pharmaceutical Co. Ltd has the following listings and related stock indices.


Stock: JPX: 4519 wb_incandescent

Stock: FSX: CUP wb_incandescent

Stock: OTC: CHGCF wb_incandescent

Stock: OTC: CHGCY wb_incandescent

Details

Headquarters:

Nihonbashi Mitsui Tower

15th Floor 1-1 Nihonbashi-Muromachi 2-chome Chuo-ku

Tokyo, 103-8324

Japan

Phone: 81 3 3281 6611

Fax: 81 3 3281 6607